相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
Yue Hao et al.
CANCER MEDICINE (2023)
The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
Alexander Marx et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti et al.
JAMA ONCOLOGY (2022)
Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Clinical Practice Guideline
Conrad B. Falkson et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial
N. Girard et al.
ANNALS OF ONCOLOGY (2021)
Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors
Zi-Ming Wang et al.
THORACIC CANCER (2021)
Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis
Binbin Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis
Yi-Te Huang et al.
FRONTIERS IN NEUROLOGY (2020)
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
Jinhyun Cho et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
Andrew L. Mammen et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study
Yuki Katsuya et al.
EUROPEAN JOURNAL OF CANCER (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review
Thomopoulou Konstantina et al.
LUNG CANCER (2019)
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Alice Tison et al.
ARTHRITIS & RHEUMATOLOGY (2019)
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Elise Alspach et al.
NATURE (2019)
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Johannes Griss et al.
NATURE COMMUNICATIONS (2019)
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Arun Rajan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Joon Seon Song et al.
FRONTIERS IN ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Anu Sharma et al.
CLINICAL CANCER RESEARCH (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
The Integrated Genomic Landscape of Thymic Epithelial Tumors
Milan Radovich et al.
CANCER CELL (2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas et al.
CANCER CELL (2018)
PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus
Emine Kilic Bagir et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
Giuseppe Giaccone et al.
LANCET ONCOLOGY (2018)
High CTLA-4 expression correlates with poor prognosis in thymoma patients
Giorgio Santoni et al.
Oncotarget (2018)
Analysis of a panel of druggable gene mutations and of ALK and PD-Ll expression in a series of thymic epithelial tumors (TETs)
Marcello Tiseo et al.
LUNG CANCER (2017)
Expression of PD-1 and PD-L1 in thymic epithelial neoplasms
Annikka Weissferdt et al.
MODERN PATHOLOGY (2017)
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
Kathryn C. Arbour et al.
PLOS ONE (2017)
ITMIG Classification of Mediastinal Compartments and Multidisciplinary Approach to Mediastinal Masses1
Brett W. Carter et al.
RADIOGRAPHICS (2017)
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
Angel Garcia-Diaz et al.
CELL REPORTS (2017)
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Peng-Fei Wang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy
Yuki Katsuya et al.
LUNG CANCER (2016)
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases
Yan Yang et al.
JOURNAL OF THORACIC DISEASE (2016)
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
Hiroyuki Inoue et al.
ONCOIMMUNOLOGY (2016)
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
N. Girard et al.
ANNALS OF ONCOLOGY (2015)
The ITMIG/IASLC Thymic Epithelial Tumors Staging Project: A Proposed Lymph Node Map for Thymic Epithelial Tumors in the Forthcoming 8th Edition of the TNM Classification of Malignant Tumors
Faiz Y. Bhora et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Mutations of epigenetic regulatory genes are common in thymic carcinomas
Yisong Wang et al.
SCIENTIFIC REPORTS (2014)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
An immune-active tumor microenvironment favors clinical response to ipilimumab
Rui-Ru Ji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Ying Xie et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Sergio A. Quezada et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Thymic epithelial turnours: A population-based study of the incidence, diagnostic procedures and therapy
Wouter K. de Jong et al.
EUROPEAN JOURNAL OF CANCER (2008)
Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas
S. Scarpino et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2007)
Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4+ T cells in thymomas
P Ströbel et al.
BLOOD (2002)
The spectrum of micronodular thymic epithelial tumours with lymphoid B-cell hyperplasia
H Tateyama et al.
HISTOPATHOLOGY (2001)
分享论文
